Vaccine manufacturer Curevac wants to cut 150 jobs. The majority of the positions will be eliminated in Tübingen, but some will also be cut in a branch in Wiesbaden.
It is primarily about the “Operations” area, which, roughly speaking, corresponds to clinical production. The company is working with its British partner GlaxoSmithKline (GSK) on the development of a new second-generation corona vaccine. It currently employs just over 1,100 people.